IFNAR1;IFNAR

Interferon alpha/beta receptor 1 (IFN-R-1) (IFN-alpha/beta receptor 1) (Cytokine receptor class-II member 1) (Cytokine receptor family 2 member 1) (CRF2-1) (Type I interferon receptor 1)

Homo sapiens (Human)

63525

557

Pending Verification

Interferon alpha/beta receptor 1 (IFN-R-1) (IFN-alpha/beta receptor 1) (Cytokine receptor class-II member 1) (Cytokine receptor family 2 member 1) (CRF2-1) (Type I interferon receptor 1)

N/A

MUTAGEN 466 466 Y->F: Impairs internalization in response to interferon. {ECO:0000269|PubMed:18056411}.; MUTAGEN 491 492 LL->AA: Impairs interaction with TYK2. {ECO:0000269|PubMed:24704786}.; MUTAGEN 496 497 EE->AA: Impairs interaction with TYK2. {ECO:0000269|PubMed:24704786}.; MUTAGEN 500 500 E->A: Impairs interaction with TYK2. {ECO:0000269|PubMed:24704786}.; MUTAGEN 501 501 K->R: Mildly reduces ubiquitination. Nearly abolishes ubiquitination and subsequent degradation; when associated with 525-R-R-526. {ECO:0000269|PubMed:15337770}.; MUTAGEN 525 526 KK->RR: Reduces ubiquitination. Nearly abolishes ubiquitination and subsequent degradation; when associated with R-501. {ECO:0000269|PubMed:15337770}.; MUTAGEN 535 535 S->A: Abolishes interaction with FBXW11 and decreases ubiquitination. {ECO:0000269|PubMed:14532120, ECO:0000269|PubMed:15337770}.; MUTAGEN 535 535 S->A: Abolishes phosphorylation at this site and interaction with SHMT2. {ECO:0000269|PubMed:24075985}.; MUTAGEN 539 539 S->A: Abolishes interaction with FBXW11 and decreases ubiquitination. {ECO:0000269|PubMed:15337770}.

MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVTFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSFTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERIENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQKGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTPVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSVFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDEYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSNEDESESKTSEELQQDFV

Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1 (PubMed:2153461, PubMed:7665574, PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:21854986). Functions in general as heterodimer with IFNAR2 (PubMed:7665574, PubMed:10049744, PubMed:21854986). Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta-subunits themselves (PubMed:7665574, PubMed:21854986). Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity). {ECO:0000250|UniProtKB:P33896, ECO:0000269|PubMed:10049744, ECO:0000269|PubMed:14532120, ECO:0000269|PubMed:15337770, ECO:0000269|PubMed:19561067, ECO:0000269|PubMed:2153461, ECO:0000269|PubMed:7665574, ECO:0000305|PubMed:21854986}.

Alternative sequence (5); Beta strand (20); Chain (1); Cross-link (3); Disulfide bond (4); Domain (4); Glycosylation (12); Helix (5); Lipidation (1); Modified residue (4); Mutagenesis (9); Natural variant (3); Region (1); Sequence caution (1); Sequence conflict (5); Signal peptide (1); Topological domain (2); Transmembrane (1); Turn (1); IFN receptors are present in all tissues and even on the surface of most IFN-resistant cells. Isoform 1, isoform 2 and isoform 3 are expressed in the IFN-alpha sensitive myeloma cell line U266B1. Isoform 2 and isoform 3 are expressed in the IFN-alpha resistant myeloma cell line U266R. Isoform 1 is not expressed in IFN-alpha resistant myeloma cell line U266R. {ECO:0000269|PubMed:8307198}.

Interferon alpha/beta receptor 1 (IFN-R-1) (IFN-alpha/beta receptor 1) (Cytokine receptor class-II member 1) (Cytokine receptor family 2 member 1) (CRF2-1) (Type I interferon receptor 1)

Recombinant

HEK293

Lyophilized

7.4-7.5

Sterile-filtered colorless solution

1mg/ml

Standard

PBS

SDS-PAGE

> 98%

RP-HPLC

-20°C

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.